Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders in the United States. Its product pipeline includes AXS-05 for major depressive disorder and resistant depression disorders, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation.